A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
作者： Salima Ismail , Malek Meskawi , Jens Hansen , Marco Bianchi , Zhe Tian
DOI: 10.1016/J.CRITREVONC.2013.12.003
关键词:
摘要: Current guidelines provide most support for the use of temsirolimus in first line therapy metastatic non-clear cell renal carcinoma (nccRCC). However, this recommendation is based on scant level 2a evidence. The objective review to examine evidence supporting patients with nccRCC as well alternative treatment options. Six studies, that assessed efficacy five agents qualified inclusion. Among recognized options nccRCC, mean weighted progression free survival values 7.9 months vs. 7.3 sunitinib 8.5 sorafenib ≈4.1 erlotinib were recorded data from 10, 74, 33 and 51 respectively. In conclusion, are a small patient sample. Sunitinib's similar but bigger sample originates phase II studies.
elsevier.com
sci-hub.se 参考文章(36)
Shanthi Marur, James Eliason, Lance K. Heilbrun, Brenda Dickow, Daryn W. Smith, Karen Baranowski, Samir Alhasan, Ulka Vaishampayan, Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma. Urology. ,vol. 72, pp. 898- 902 ,(2008) , 10.1016/J.UROLOGY.2008.05.032
Brian I Rini, Bernard Escudier, Piotr Tomczak, Andrey Kaprin, Cezary Szczylik, Thomas E Hutson, M Dror Michaelson, Vera A Gorbunova, Martin E Gore, Igor G Rusakov, Sylvie Negrier, Yen-Chuan Ou, Daniel Castellano, Ho Yeong Lim, Hirotsugu Uemura, Jamal Tarazi, David Cella, Connie Chen, Brad Rosbrook, Sinil Kim, Robert J Motzer, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial The Lancet. ,vol. 378, pp. 1931- 1939 ,(2011) , 10.1016/S0140-6736(11)61613-9
Ellen A. Ronnen, G. Varuni Kondagunta, Nicole Ishill, Lesley Spodek, Paul Russo, Victor Reuter, Jennifer Bacik, Robert J. Motzer, Treatment outcome for metastatic papillary renal cell carcinoma patients Cancer. ,vol. 107, pp. 2617- 2621 ,(2006) , 10.1002/CNCR.22340
Maxine Sun, Giovanni Lughezzani, Paul Perrotte, Pierre I. Karakiewicz, Treatment of metastatic renal cell carcinoma Nature Reviews Urology. ,vol. 7, pp. 327- 338 ,(2010) , 10.1038/NRUROL.2010.57
Alain Ravaud, Hervé Wallerand, Stéphane Culine, Jean-Christophe Bernhard, Patricia Fergelot, Karim Bensalah, Jean-Jacques Patard, Update on the Medical Treatment of Metastatic Renal Cell Carcinoma European Urology. ,vol. 54, pp. 315- 325 ,(2008) , 10.1016/J.EURURO.2008.04.056
Stephen DW Beck, Manish I Patel, Mark E Snyder, Michael W Kattan, Robert J Motzer, Victor E Reuter, Paul Russo, None, Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma Annals of Surgical Oncology. ,vol. 11, pp. 71- 77 ,(2004) , 10.1007/BF02524349
Ian Wright, Anil Kapoor, Current systemic management of metastatic renal cell carcinoma - first line and second line therapy. Current Opinion in Supportive and Palliative Care. ,vol. 5, pp. 211- 221 ,(2011) , 10.1097/SPC.0B013E3283490418
Pedro Sánchez, Emiliano Calvo, Ignacio Durán, Non-clear cell advanced kidney cancer: is there a gold standard? Anti-Cancer Drugs. ,vol. 22, ,(2011) , 10.1097/01.CAD.0000390767.85658.83
Janice P. Dutcher, Paul de Souza, David McDermott, Robert A. Figlin, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Gary Hudes, Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies Medical Oncology. ,vol. 26, pp. 202- 209 ,(2009) , 10.1007/S12032-009-9177-0
Ana M. Molina, Darren R. Feldman, Michelle S. Ginsberg, Glenn Kroog, Satish K. Tickoo, Xiaoyu Jia, Murielle Georges, Sujata Patil, Michael S. Baum, Victor E. Reuter, Robert J. Motzer, Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma Investigational New Drugs. ,vol. 30, pp. 335- 340 ,(2012) , 10.1007/S10637-010-9491-6